Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport—an update
Q Mao, JD Unadkat - The AAPS journal, 2015 - Springer
The human breast cancer resistance protein (BCRP, gene symbol ABCG2) is an ATP-
binding cassette (ABC) efflux transporter. It was so named because it was initially cloned …
binding cassette (ABC) efflux transporter. It was so named because it was initially cloned …
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
K Fujita, Y Kubota, H Ishida… - World journal of …, 2015 - pmc.ncbi.nlm.nih.gov
Irinotecan hydrochloride is a camptothecin derivative that exerts antitumor activity against a
variety of tumors. SN-38 produced in the body by carboxylesterase is the active metabolite of …
variety of tumors. SN-38 produced in the body by carboxylesterase is the active metabolite of …
[HTML][HTML] Genophenotypic factors and pharmacogenomics in adverse drug reactions
R Cacabelos, V Naidoo, L Corzo, N Cacabelos… - International journal of …, 2021 - mdpi.com
Adverse drug reactions (ADRs) rank as one of the top 10 leading causes of death and
illness in developed countries. ADRs show differential features depending upon genotype …
illness in developed countries. ADRs show differential features depending upon genotype …
Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in …
K Kurose, E Sugiyama, Y Saito - Drug metabolism and …, 2012 - jstage.jst.go.jp
Drug lag, recently discussed extensively in Japan, can be divided into two phases: clinical
development time and application review time. The former factor is still an important problem …
development time and application review time. The former factor is still an important problem …
Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer
T Yoshikawa, M Sasako, S Yamamoto… - Journal of British …, 2009 - academic.oup.com
Background Locally advanced gastric cancer with extensive lymph node metastasis is
usually considered unresectable and so treated by chemotherapy. This trial explored the …
usually considered unresectable and so treated by chemotherapy. This trial explored the …
Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review
JC Stingl, H Bartels, R Viviani, ML Lehmann… - Pharmacology & …, 2014 - Elsevier
UDP-glucuronosyltransferases (UGT) catalyze the biotransformation of many endobiotics
and xenobiotics, and are coded by polymorphic genes. However, knowledge about the …
and xenobiotics, and are coded by polymorphic genes. However, knowledge about the …
The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy
FC Passero Jr, D Grapsa, KN Syrigos… - Expert review of …, 2016 - Taylor & Francis
Introduction: Patients with advanced and metastatic pancreatic cancer refractory to
gemcitabine based therapy have a dismal prognosis and limited therapeutic options …
gemcitabine based therapy have a dismal prognosis and limited therapeutic options …
Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years
M Panczyk - World Journal of Gastroenterology: WJG, 2014 - pmc.ncbi.nlm.nih.gov
During the past two decades the first sequencing of the human genome was performed
showing its high degree of inter-individual differentiation, as a result of large international …
showing its high degree of inter-individual differentiation, as a result of large international …
UGT1A1 polymorphisms in cancer: impact on irinotecan treatment
M Takano, T Sugiyama - Pharmacogenomics and personalized …, 2017 - Taylor & Francis
Mutations in the UGT1A1 gene have been implicated in Gilbert syndrome, which shows mild
hyperbilirubinemia, and a more aggressive childhood subtype, Crigler–Najjar syndrome. To …
hyperbilirubinemia, and a more aggressive childhood subtype, Crigler–Najjar syndrome. To …
Clinically relevant genetic variations in drug metabolizing enzymes
N Pinto, M Eileen Dolan - Current drug metabolism, 2011 - ingentaconnect.com
In the field of pharmacogenetics, we currently have a few markers to guide physicians as to
the best course of therapy for patients. For the most part, these genetic variants are within a …
the best course of therapy for patients. For the most part, these genetic variants are within a …